Medicure

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Withdrawn

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

Earlier

Feb 16, 2024TrialOral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

Aug 4, 2017FDALivalo — NIKITA

Jul 14, 2017FDALivalo — ZYPITAMAG

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

LivaloJan 19, 2031

Regulatory

Regulatory Timeline

19981 event

FDAMay 14

Aggrastat — AGGRASTAT

Application NDA020912 (NDA)

20021 event

FDAMay 17

Aggrastat — AGGRASTAT

Application NDA020913 (NDA)

20091 event

FDAAug 3

Livalo — LIVALO

Application NDA022363 (NDA)

20172 events

FDAAug 4

Livalo — NIKITA

Application NDA209875 (NDA)

FDAJul 14

Livalo — ZYPITAMAG

Application NDA208379 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)